Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 4/20 | 0.38 |
| ▸ | TYMP | P19971 | 1/20 | 0.34 |
| ▸ | DUT | P33316 | 4/20 | 0.34 |
| ▸ | P2RY2 | P41231 | 7/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 4/20 | 0.34 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.34 |
| ▸ | NT5E | P21589 | 1/20 | 0.33 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25397635 | 0.86 | TK2 (0.38) | TYMP | |
| SCHEMBL4393008 | 0.86 | TYMP (0.45) | P2RY14TYMPDUTP2RY2P2RY12 | |
| SCHEMBL25402034 | 0.86 | TK2 (0.38) | TYMP | |
| SCHEMBL25397998 | 0.86 | HSP90AA1 (0.44) | P2RY14TYMPP2RY6NT5E | |
| SCHEMBL25399237 | 0.85 | SLC28A1 (0.46) | P2RY14TYMPDUTP2RY2P2RY12 | |
| SCHEMBL25398449 | 0.82 | DUT (0.45) | P2RY14TYMPDUTP2RY2P2RY12 | |
| SCHEMBL25605750 | 0.82 | P2RY14 (0.38) | P2RY14TYMPDUTP2RY2P2RY12 | |
| SCHEMBL13134623 | 0.80 | TYMP (0.34) | P2RY14TYMPP2RY2P2RY6NT5E | |
| SCHEMBL13134608 | 0.80 | TYMP (0.34) | P2RY14TYMPP2RY2P2RY6NT5E | |
| SCHEMBL26653344 | 0.79 | TYMP (0.44) | P2RY14TYMPDUTP2RY2P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145654-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| EP-4493573-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | Rome Therapeutics, Inc. (US) | 2025-01-22 | — | — | EP | disclosed |
| US-12187758-B2 | Compounds and methods for treating disease | ROME THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2023178133-A9 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023178133-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | P2RY14 4537/4885TYMP 310/4885DUT 1327/4885 |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | P2RY14 4537/4885TYMP 310/4885DUT 1327/4885 |
| US-20250145654-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | P2RY14 4537/4885TYMP 310/4885DUT 1327/4885 |
| US-12187758-B2 | Compounds and methods for treating disease | EHMT1, POLRMT, RNASE1 | P2RY14 4537/4885TYMP 310/4885DUT 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.